- Home
- Publications
- Publication Search
- Publication Details
Title
Relapsed Hodgkin Lymphoma: Management Strategies
Authors
Keywords
Hodgkin lymphoma, Relapsed disease, Refractory disease, Risk stratification, Autologous stem cell transplant, Reduced-intensity conditioning allogeneic stem cell transplant, Brentuximab vedotin, Bendamustine, Histone deacetylase inhibitors, Everolimus, Panobinostat, Lenalidomide, Rituximab, Immunochemotherapy, Elderly patients
Journal
Current Hematologic Malignancy Reports
Volume 9, Issue 3, Pages 284-293
Publisher
Springer Nature
Online
2014-06-19
DOI
10.1007/s11899-014-0220-7
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies
- (2014) Nancy L Bartlett et al. Journal of Hematology & Oncology
- GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma
- (2013) Eliza A. Hawkes et al. ANNALS OF HEMATOLOGY
- Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation†
- (2013) C. Martínez et al. ANNALS OF ONCOLOGY
- Phase I Study of Panobinostat plus Everolimus in Patients with Relapsed or Refractory Lymphoma
- (2013) Y. Oki et al. CLINICAL CANCER RESEARCH
- Relapsed Hodgkin Lymphoma in Older Patients: A Comprehensive Analysis From the German Hodgkin Study Group
- (2013) Boris Böll et al. JOURNAL OF CLINICAL ONCOLOGY
- Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
- (2013) Theresa Hahn et al. JOURNAL OF CLINICAL ONCOLOGY
- Early thymus and activation-regulated chemokine (TARC) reduction and response following panobinostat treatment in patients with relapsed/refractory Hodgkin lymphoma following autologous stem cell transplant
- (2013) Simon J. Harrison et al. LEUKEMIA & LYMPHOMA
- Brentuximab vedotin (SGN-35) in patients with transplant-naive relapsed/refractory Hodgkin lymphoma
- (2013) Stephanie Sasse et al. LEUKEMIA & LYMPHOMA
- Clinical experience of bendamustine in relapsed or refractory Hodgkin lymphoma: a retrospective analysis of the French compassionate use program in 28 patients
- (2013) Hervé Ghesquières et al. LEUKEMIA & LYMPHOMA
- Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study
- (2012) S. J. Proctor et al. BLOOD
- Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experience
- (2012) A. Rothe et al. BLOOD
- Gene expression profiling of microdissected Hodgkin Reed-Sternberg cells correlates with treatment outcome in classical Hodgkin lymphoma
- (2012) C. Steidl et al. BLOOD
- Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation
- (2012) A. K. Gopal et al. BLOOD
- Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma
- (2012) Gaetano Corazzelli et al. BRITISH JOURNAL OF HAEMATOLOGY
- Positron emission tomography response at the time of autologous stem cell transplantation predicts outcome of patients with relapsed and/or refractory Hodgkin's lymphoma responding to prior salvage therapy
- (2012) R. Devillier et al. HAEMATOLOGICA
- Panobinostat in Patients With Relapsed/Refractory Hodgkin's Lymphoma After Autologous Stem-Cell Transplantation: Results of a Phase II Study
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
- (2012) Alison J. Moskowitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Gene Expression–Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
- (2012) David W. Scott et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Significance of FDG-PET in Relapsed or Refractory Classical Hodgkin Lymphoma Treated with Standard Salvage Chemotherapy and Autologous Stem Cell Transplantation
- (2011) Jacob P. Smeltzer et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma
- (2011) T. A. Fehniger et al. BLOOD
- A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era
- (2011) A. M. Evens et al. BLOOD
- Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma
- (2011) C. H. Moskowitz et al. BLOOD
- High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma
- (2011) N Puig et al. BONE MARROW TRANSPLANTATION
- A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
- (2011) M. A. Fanale et al. CLINICAL CANCER RESEARCH
- Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial
- (2011) Anas Younes et al. LANCET ONCOLOGY
- A phase 2 study of vorinostat for treatment of relapsed or refractory Hodgkin lymphoma: Southwest Oncology Group Study S0517
- (2011) Mark H. Kirschbaum et al. LEUKEMIA & LYMPHOMA
- The Unique Characteristics and Management of Patients Over 60 Years of Age with Classic Hodgkin Lymphoma
- (2011) Teresa V. Halbsguth et al. Current Hematologic Malignancy Reports
- Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma
- (2010) A. J. Moskowitz et al. BLOOD
- Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
- (2010) Anas Younes et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predictive value of early 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) during salvage chemotherapy in relapsing/refractory Hodgkin lymphoma (HL) treated with high-dose chemotherapy
- (2009) Luca Castagna et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma
- (2009) Andres Forero-Torres et al. BRITISH JOURNAL OF HAEMATOLOGY
- Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines
- (2008) D. Buglio et al. BLOOD
- Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden
- (2008) S. Y. Kristinsson et al. BLOOD
- Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
- (2008) P. Anderlini et al. HAEMATOLOGICA
- Treatment of Hodgkin lymphoma: the past, present and future
- (2008) Andrew M Evens et al. Nature clinical practice. Oncology
- Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma
- (2007) Yasuhiro Oki et al. CANCER
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started